In 2019. the FDA approved the first new medication for major depression in decades. The drug is a nasal spray called esketamine, derived from ketamine—an anesthetic that has made waves for its surprising antidepressant effect. Our Yale psychiatrists discuss its benefits and limitations.| Yale Medicine
Worldwide about 10% of pregnant women and 13% of women who have just given birth experience a mental disorder, primarily depression. In developing countries this is even higher, i.e. 15.6% during pregnancy and 19.8% after child birth. In severe cases mothers’ suffering might be so severe that they may even commit suicide. In addition, the affected mothers cannot function properly. As a result, the children’s growth and development may be negatively affected as well. Maternal mental disord...| www.who.int
The FDA approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults.| U.S. Food and Drug Administration
Objective To determine whether a single low dose of esketamine administered after childbirth reduces postpartum depression in mothers with prenatal depression. Design Randomised, double blind, placebo controlled trial with two parallel arms. Setting Five tertiary care hospitals in China, 19 June 2020 to 3 August 2022. Participants 364 mothers aged ≥18 years who had at least mild prenatal depression as indicated by Edinburgh postnatal depression scale scores of ≥10 (range 0-30, with higher...| The BMJ
Welcome to Conscious Health & Wellness Center,contact us now for your innovative Ketamine Therapy in Los Angeles, CA, offering a new path to those seeking mental health solutions beyond traditional treatments.| Conscious Health Center
Unlocking new paths to wellness, TMS Therapy Los Angeles targets the neurological roots of mood disorders with precision at Conscious Health.| Conscious Health Center
